Neuroscience.
Neuropeptide analogues and sleep-related research, with attention to model and study-design limitations.
3 source-linked dossiers. Categories organize research context, not approved uses or promised benefits. Evidence labels refer to the sources discussed in each record.

DSIP
Delta sleep-inducing peptide
Sleep physiology and small early human studies.

Selank
Tuftsin-related analogue
Neurobehavioral and exploratory clinical research.

Semax
ACTH-related analogue
Neurotrophic signaling in experimental models.
Evidence labels describe the cited sources, not a complete systematic review, a safety rating or regulatory approval. This archive does not yet cover every peptide.
Read the background
Difelikefalin: A Peptide for a Specific CKD-Associated Itch Question
Difelikefalin addresses a specific itch question in adults receiving hemodialysis, rather than chronic kidney disease as a whole.
Semaglutide and Alcohol Craving: The Trials Do Not All Say the Same Thing
Semaglutide alcohol-use research contains promising findings and results that resist a simple headline.
Ziconotide: A Conopeptide with a Very Specific Clinical Role
Ziconotide is a conopeptide medicine with a highly specific pain-management setting and route. Its N-type calcium-channel binding helps explain the research rationale, but the product record also contains substantial safety restrictions.
How to Read a Peptide Research Paper Critically
Start a peptide paper with a concrete question: what was tested, against what comparison, and what was measured?
Peptide Clinical Trial Endpoints: Read Beyond the Headline
A peptide trial can measure a hormone concentration, a symptom score, a change in weight and an adverse event in the same study.
Preclinical vs Clinical Peptide Evidence: What Changes?
Research peptides can produce an interesting result in cultured cells long before there is a useful answer about people.